Tempus AI, Inc. (TEM) Stock Analysis

Company Overview

Tempus AI, Inc. operates as a healthcare technology company in the United States, offering the Tempus platform which functions as a closed-loop, full-stack solution featuring bi-directional integrations between a clinician's desktop, laboratory diagnostic capabilities, an analytics platform, and a repository of multimodal data. The company functions within the Healthcare sector and the Health Information Services industry, positioning itself to leverage data-driven insights across the medical ecosystem. Tempus AI, Inc. holds a market capitalization of $8.71B and reported annual revenue of $1.27B over the trailing twelve months, supported by an employee base of 3800. These valuation and revenue figures indicate that the market assigns a significant premium to the company's technology stack and data repository, reflecting high expectations for its ability to transform healthcare workflows and diagnostic precision despite its current profitability challenges.

Financial Health

The company reported a revenue of $1.27B in the trailing twelve months, yet it posted a net income of $-245,028,000 and an EBITDA of $-171,512,992, revealing a substantial gap between top-line growth and bottom-line results that highlights a heavy cost structure or significant investments in expansion. This negative free cash flow of $-112,498,872 suggests that the company is currently burning cash, which limits immediate financial flexibility and relies heavily on existing liquidity to fund operations. The company maintains a gross margin of 62.7%, which is robust for a technology-driven service provider, but this is offset by an operating margin of -16.7% and a profit margin of -19.3%, indicating that operating expenses and general administrative costs are eroding the majority of gross profits. On the balance sheet, the company holds $755.00M in cash against total debt of $1.33B, resulting in a debt-to-equity ratio of 270.11, which characterizes the financial position as highly leveraged rather than conservative. Despite this leverage, the current ratio stands at 3.13, indicating that the company possesses more than three times the current assets needed to cover its short-term liabilities, suggesting adequate liquidity management. Return on Equity is reported at -89.5% and Return on Assets is -9.7%, metrics that reveal that management is currently generating negative returns on capital deployed, which is typical for high-growth biotech and healthcare technology firms but signals a need for future profitability to sustain shareholder value.

Valuation Assessment

The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -780.46, implying that the market is pricing in significant future earnings improvements to justify the current valuation multiple. The price-to-book ratio is 17.67, indicating that the stock trades at a substantial premium of nearly 18 times its book value, which reflects high market confidence in the company's intangible assets and future revenue potential rather than current tangible worth. Alternative valuation metrics show a price-to-sales ratio of 6.85 and an EV/EBITDA of -54.14, suggesting that investors are valuing the company primarily on its revenue generation capacity and data platform scale rather than current cash flow profitability. The stock has traded between a 52-week high of $104.32 and a 52-week low of $36.22, with the current price sitting at a level that implies significant volatility and a distance from the recent peak, highlighting the sensitivity of the valuation to market sentiment in the healthcare technology sector. The beta value is N/A, meaning standard market volatility comparisons relative to the broader market index cannot be calculated from the available data.

Growth & Income

Revenue growth over the year-over-year period is 83.0%, demonstrating a rapid expansion in top-line sales, whereas earnings growth is N/A due to the company's ongoing net losses, implying that the company is prioritizing market capture and platform development over immediate earnings generation. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available earnings and cash reserves back into the business to fuel further technological advancement and operational scaling rather than distributing income to shareholders. This strategy aligns with the company's high revenue growth rate and negative profitability, suggesting a lifecycle stage focused on establishing a dominant market position in health information services. The overall growth and income profile is defined by aggressive top-line expansion and a complete reliance on retained earnings to fund operations, with no current income distribution to investors.